Fig. 2
Risk assessment plots showing model enhancement in a AKI, b severe (KDIGO 2–3) AKI, c RRT, and d 90-day mortality. Dashed lines (baseline model) represent clinical risk models and solid lines represent new risk models with uNGAL. The gray areas between the solid and the dashed lines represent IDIevents (area between black lines) and IDInonevents (area between red lines). a Visually estimated from the curves, adding uNGAL to the clinical risk model improves separation of patients who will develop AKI when the risk of the event is more than ≈ 45%, and discrimination of patients who will not develop AKI when the risk of the event is less than ≈ 50%. b With severe AKI, uNGAL added to the clinical risk model improves distinguishing KDIGO 2–3 patients when the risk of the event (= severe AKI) is more than ≈ 25% and helps separating those with KDIGO stage 0–1 when the risk of the event is less than ≈ 30%. c Adding uNGAL to the clinical risk model improves the performance for assigning individuals that will end up with RRT when the risk of the event is lower than ≈ 40%, and enhances discrimination of those not ending up with RRT when the risk of the event is lower than ≈ 10%. d Corresponding statistics in Table 2, RAPs for the clinical 90-day mortality risk model and for the new model with uNGAL added illustrate that uNGAL offers only minimal enhancement separating those who will die by day 90 when the risk of the event is > 40%